Literature DB >> 35038000

NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.

C Alcalá1, L Cubas2, S Carratalá2, F Gascón3, C Quintanilla-Bordás2, S Gil-Perotín2, D Gorriz2, F Pérez-Miralles2, R Gasque2, J Castillo2, B Casanova2.   

Abstract

INTRODUCTION: Levels of neuro-filament light chain (NFL) correlate with clinical and radiological activity in multiple sclerosis (MS) and have been used as a surrogate biomarker of axonal destruction related to inflammatory activity. The main objective of this work is to explore the specific contribution of acute inflammation within the spinal cord to the elevation of NFL levels. PATIENTS AND METHODS: MS patients with a baseline study of NFL at diagnosis of the disease and a brain and spinal cord MRI scan were selected. Patients were classified according to the presence, number and location of gadolinium enhancing lesion (GEL) and the relationship between NFL levels and both brain and spinal cord GEL were explored.
RESULTS: Seventy-seven patients were selected. NFL levels were significantly higher in patients with only one GEL restricted to the brain than those without GEL (1702 pg/ml vs 722.7 pg/mL, p = 0.03) and correlated with number. However, no differences were seen among patients with GEL limited to the spinal cord and those without GEL (735.2 pg/ml vs 722.7 pg/mL).
CONCLUSION: Our study reaffirms the value of NFL levels in monitoring asymptomatic inflammatory activity in the brain measured by GEL. However, NFL concentration is not as useful when only inflammatory activity occurs in the spinal cord.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Gadolinium-enhancing lesion; Multiple sclerosis; NFL; Spinal cord

Mesh:

Substances:

Year:  2022        PMID: 35038000     DOI: 10.1007/s00415-021-10926-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  Spinal cord pathology in multiple sclerosis.

Authors:  Hans Lassmann
Journal:  Lancet Neurol       Date:  2015-03-04       Impact factor: 44.182

2.  Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.

Authors:  J W Thorpe; D Kidd; I F Moseley; B E Kenndall; A J Thompson; D G MacManus; W I McDonald; D H Miller
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

4.  Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype.

Authors:  G J Nijeholt; E Bergers; W Kamphorst; J Bot; K Nicolay; J A Castelijns; J H van Waesberghe; R Ravid; C H Polman; F Barkhof
Journal:  Brain       Date:  2001-01       Impact factor: 13.501

5.  Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Authors:  Nelly Siller; Jens Kuhle; Muthuraman Muthuraman; Christian Barro; Timo Uphaus; Sergiu Groppa; Ludwig Kappos; Frauke Zipp; Stefan Bittner
Journal:  Mult Scler       Date:  2018-03-15       Impact factor: 6.312

6.  Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Authors:  Christian Barro; Pascal Benkert; Giulio Disanto; Charidimos Tsagkas; Michael Amann; Yvonne Naegelin; David Leppert; Claudio Gobbi; Cristina Granziera; Özgür Yaldizli; Zuzanna Michalak; Jens Wuerfel; Ludwig Kappos; Katrin Parmar; Jens Kuhle
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

7.  Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions.

Authors:  N Evangelou; G C DeLuca; T Owens; M M Esiri
Journal:  Brain       Date:  2004-11-17       Impact factor: 13.501

Review 8.  MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis.

Authors:  Achim Gass; Maria A Rocca; Federica Agosta; Olga Ciccarelli; Declan Chard; Paola Valsasina; Jonathan C W Brooks; Antje Bischof; Philipp Eisele; Ludwig Kappos; Frederik Barkhof; Massimo Filippi
Journal:  Lancet Neurol       Date:  2015-03-04       Impact factor: 44.182

9.  Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology.

Authors:  Christopher P Gilmore; Lars Bö; Trudy Owens; James Lowe; Margaret M Esiri; Nikos Evangelou
Journal:  Brain Pathol       Date:  2006-07       Impact factor: 6.508

10.  Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.

Authors:  Jens Kuhle; Tatiana Plavina; Christian Barro; Giulio Disanto; Dipen Sangurdekar; Carol M Singh; Carl de Moor; Bob Engle; Bernd C Kieseier; Elizabeth Fisher; Ludwig Kappos; Richard A Rudick; Jaya Goyal
Journal:  Mult Scler       Date:  2019-11-04       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.